ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 9, 2015

9:00AM-11:00AM
Abstract Number: 1870
A Lupus-Associated Variant in Purine Nucleoside Phosphorylase (PNP) Causes Cell Cycle Abnormalities
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1389
A Meta-Analysis of the Prevalence of the Ocular Manifestations in All Inflammatory Rheumatic Diseases
Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II
9:00AM-11:00AM
Abstract Number: 1443
A Multiple Ascending-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirogabalin in Healthy Elderly Subjects
Pain: Basic and Clinical Aspects Poster
9:00AM-11:00AM
Abstract Number: 1770
A New Perspective in Extracorporeal Immunotherapy of Systemic Lupus Erythematosus: Dnase I-Based Blood Perfusion Experiment Using Rat Model
Systemic Lupus Erythematosus - Animal Models Poster II
9:00AM-11:00AM
Abstract Number: 1800
A Novel Anti-CD28 Domain Antibody Antagonist Shows a Favorable Pharmacokinetic, Pharmacodynamic and Safety Profile
Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II
9:00AM-11:00AM
Abstract Number: 1628
A Novel Histone Deacetylase 6 Inhibitor, CKD-H059 Inhibits the Inflammatory Response in Rheumatoid Arthritis
Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1946
A Novel HLA-DRB1*10:01 Restricted T Cell Epitope from Citrullinated Type II Collagen Relevant for Rheumatoid Arthritis
T cell Biology and Targets in Autoimmune Disease Poster I
9:00AM-11:00AM
Abstract Number: 1470
A Population-Based Study of Outcomes of Patients with Juvenile Idiopathic Arthritis (JIA) Compared to Non-JIA Subjects    
Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1110
A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster
9:00AM-11:00AM
Abstract Number: 1647
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II
9:00AM-11:00AM
Abstract Number: 1201
A Short Training on Solution Focused Approach May be Helpful in Providing Psychological Support Skills to Nurses Involved in Rheumatoid Arthritis
Education Poster (ARHP): Education/Community Programs
9:00AM-11:00AM
Abstract Number: 1960
a Structured and Extensive Training Program on Vascular Ultrasound, Results in an Excellent Agreement Between Ultrasound and Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis
Vasculitis Poster II
9:00AM-11:00AM
Abstract Number: 1642
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate Inadequate Responders with Rheumatoid Arthritis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II
9:00AM-11:00AM
Abstract Number: 1654
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II
9:00AM-11:00AM
Abstract Number: 1503
A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Rheumatoid Arthritis - Clinical Aspects Poster II
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 72
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology